Sandrock Alfred 4

What Happened

• Alfred Sandrock, President, CEO and a director of Voyager Therapeutics (VYGR), received equity grants on Feb 6, 2026: 86,250 restricted stock units (RSUs) and a stock option/derivative covering 402,500 shares. Both grants show an acquisition price of $0 (these are compensation awards, not open‑market purchases).

Key Details

• Transaction date: Feb 6, 2026; Form 4 filed Feb 10, 2026 (timely filing).
• RSUs: 86,250 RSUs awarded (F1). Each RSU converts to one share upon vesting; grant price $0.
• Option/derivative: 402,500-share option/award (listed as a derivative acquisition) (F3); grant price $0.
• Additional note (F2): Reporting person acquired 5,000 shares under the company ESPP since the last Form 4.
• Vesting summary:
  • RSUs vest over 3 years (1/3 after 1 year, then 1/3 each year thereafter; vesting commencement = Feb 6, 2026) (F1).
  • Option vests over 4 years, with 1/48th vesting one month after Feb 6, 2026 and monthly thereafter (F3).
• Shares owned after the transactions were not specified in the provided excerpt.

Context

• These are compensation grants (awards), not sales or open‑market purchases — they represent future economic interest subject to vesting and continued service. The option grant is not an exercise; it grants the right to buy shares in the future according to the vesting schedule. The RSUs will convert to actual shares only as they vest.